Waverley Pharma (TSXV:WAVE) Tax Provision : C$0.00 Mil (TTM As of Sep. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Waverley Pharma Tax Provision?

Waverley Pharma's tax provision for the three months ended in Sep. 2024 was C$0.00 Mil. Its tax provision for the trailing twelve months (TTM) ended in Sep. 2024 was C$0.00 Mil.

Waverley Pharma Tax Provision Historical Data

The historical data trend for Waverley Pharma's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Waverley Pharma Tax Provision Chart

Waverley Pharma Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Tax Provision

Get a 7-Day Free Trial

Waverley Pharma Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Sep24
Tax Provision	Get a 7-Day Free Trial															-	-	-	-	-

Waverley Pharma Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.00 Mil.

Waverley Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Waverley Pharma Inc (TSXV:WAVE) » Definitions » Tax Provision

Comparable Companies

Traded in Other Exchanges

5GZ:Germany

Address

1250 Waverley Street, Suite 4, Winnipeg, MB, CAN, R3T 6C6

Website

https://www.waverleypharma.com

Waverley Pharma Inc is a biopharmaceutical company. It is engaged in the research, development, and commercialization of human therapeutics that focuses on oncology. The company products pipeline includes Bortezomib, Pemetrexed, Capecitabine, and Temozolomide, among others.

Executives